Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26664252 | 0.79 | TRPV3 (0.47) | MAPTKDM4ETHRBDPP4NPSR1 | |
| SCHEMBL26664244 | 0.78 | HPGD (0.48) | MAPTKDM4ENPSR1CNR1GPR35 | |
| SCHEMBL26664432 | 0.78 | NAMPT (0.45) | MAPTKDM4ETHRBDPP4NPSR1 | |
| SCHEMBL25939333 | 0.75 | THRB (0.53) | MAPTKDM4ETHRBDPP4TRPV3 | |
| SCHEMBL26664201 | 0.75 | HPGD (0.47) | MAPTKDM4ETHRBNPSR1TRPV3 | |
| SCHEMBL12211468 | 0.75 | MEN1 (0.48) | MAPTKDM4ETHRBDPP4NPSR1 | |
| SCHEMBL1462885 | 0.73 | MAPT (0.46) | MAPTKDM4ETHRBDPP4NPSR1 | |
| SCHEMBL26930284 | 0.72 | GPR119 (0.56) | MAPTKDM4ETHRBDPP4TRPV3 | |
| SCHEMBL20135279 | 0.72 | KDM4E (0.46) | MAPTKDM4ETHRBDPP4CNR1 | |
| SCHEMBL14157519 | 0.72 | SMN1; SMN2 (0.47) | MAPTKDM4ETHRBDPP4TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025111409-A1 | HETEROCYCLIC COMPOUNDS OF FORMULA (I) FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY VIA MODULATION OF SMN2 SPLICING | BIOGEN MA INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-119866329-A | Heterocyclic compounds for the treatment of huntington's disease | 渤健马萨诸塞州股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-4526292-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | Biogen MA Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | MAPT 5/4885KDM4E 2060/4885THRB 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.